Table 2 Summary of TE arrhythmias in overall population. All Participants as Treated
Treatment | n (%) | Difference in %a (95% CI) | P-value |
|---|---|---|---|
TE Sinus Bradycardia | |||
Neostigmine/glycopyrrolate, n = 51 | 4 (7.8) | (ref.) | |
Sugammadex 2 mg/kg, n = 105 | 1 (1.0) | − 6.7 (− 17.5, − 0.8) | 0.026 |
Sugammadex 4 mg/kg, n = 107 | 2 (1.9) | − 6.2 (− 17.3, 0.2) | 0.058 |
Sugammadex 16 mg/kg, n = 68 | 5 (7.4) | − 2.0 (− 17.8, 8.6) | 0.730 |
TE Sinus Tachycardia | |||
Neostigmine/glycopyrrolate, n = 51 | 11 (21.6) | (ref.) | |
Sugammadex 2 mg/kg, n = 105 | 7 (6.7) | − 14.9 (− 28.8, − 4.0) | 0.007 |
Sugammadex 4 mg/kg, n = 107 | 10 (9.3) | − 12.2 (− 26.1, − 0.8) | 0.036 |
Sugammadex 16 mg/kg, n = 68 | 6 (8.8) | − 9.9 (− 27.6, 3.6) | 0.158 |
Other TE Cardiac Arrhythmias | |||
Neostigmine/glycopyrrolate, n = 51 | 1 (2.0) | (ref.) | |
Sugammadex 2 mg/kg, n = 105 | 1 (1.0) | −0.9 (− 9.4, 4.0) | 0.637 |
Sugammadex 4 mg/kg, n = 107 | 0 | − 2.1 (− 10.6, 1.5) | 0.134 |
Sugammadex 16 mg/kg, n = 68 | 1 (1.5) | −1.7 (− 14.7, 5.8) | 0.577 |